Access to Information Orders
Decision Information
• Records relating to drug company submission for reimbursement of a named drug in the Special Drugs Program – correspondence, agreement, briefing note, submissions
• Section 17(1)(a) (third party information) – partly upheld
• Section 13(1) (advice to government) – upheld
• Section 18(1)(a), (c), (d), (g) (economic and other interests) – not upheld
• Late raising of discretionary exemption – allowed
• Section 23 (Public Interest Override) – not applied
• Four records ordered disclosed (out of 39 records)
Decision Content
NATURE OF THE APPEAL:
The Ministry of Health and Long-Term Care (the Ministry) received a request under the Freedom of Information and Protection of Privacy Act (the Act) for:
All documentation including communications to or from the Ministry, internal memoranda of the Ministry, correspondence, technical or other reports or data, submissions, opinions, contracts and other relevant information relating to the application for the listing and the listing of the drug [a specific drug] in the Special Drugs Program [SDP] of the Ministry.
The requester stated further that the “…records relate to the availability to patients, through the [SDP], of a drug used in the treatment of anemia, in individuals suffering from chronic renal failure or undergoing chemotherapy, among others. The disclosure of the requested records is accordingly in the public interest.”
FIPPA REQUEST - A-2003-01116 - INDEX OF RECORDS
Item # |
DESCRIPTION (description of record e.g., title, correspondent names, dates, etc.) |
# of Pages |
RELEASE |
SEVER (Yes/No) |
SECTION (FIPPA exemption section(s) #(s) applied |
1 |
Letter from Amgen to Office of the Minister of Health |
1 |
Access Denied |
Yes |
17(1)(a)(b)(c)
18(1)(c)(d)(g) |
1A |
Letter from Amgen to Drug Programs Branch (DPB) |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
1B |
Letter from DPB to Amgen |
1 |
Access Denied |
Yes |
17(1)(a)(c) |
1C |
Letter from Amgen to Drug Programs Branch (DPB) |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
1D |
Letter from Amgen to Drug Programs Branch (DPB) |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
1E |
Letter from Amgen to Drug Programs Branch (DPB) |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
1F |
Letter from DPB to Amgen |
1 |
Access Denied |
Yes |
17(1)(a)(c) |
1G |
Letter from Amgen to Drug Programs Branch (DPB) |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) 2(1)(f)(h)[21(2)(e)(i)] |
1H |
Letter from Amgen to Ministry
+ Attachment |
2
4 |
Access Denied
Access Denied |
Yes
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g)
19 |
1I |
Letter from DPB to Amgen |
1 |
Access Denied |
Yes |
17(1)(a)(c) |
1J |
Letter from Amgen to Ministry
|
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
2 |
Letter from Amgen to DPB |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
3 |
Letter from DPB to Amgen |
2 |
Access Denied |
Yes |
17(1)(a)(c) |
4 |
Letter from Amgen to DPB |
2 |
Access Denied
|
Yes
|
17(1)(a)(b)(c) 18(1)(c)(d)(g)
|
5-8 |
Correspondence from Drug Programs Branch to DQTC reviewers |
8 |
Partial Disclosure e |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d) 2(1)(h)and 21(1)[21(2)(f)(h)] |
9-13 |
DQTC reviewers reports |
13 |
Access Denied |
Yes |
17(1)(a)(b)(c) 13(1) 18(1)(c)(d) 2(1)(h)and 21(1)[21(2)(f)(h)] |
14 |
Letter from DPB to Amgen |
1 |
Access Denied |
Yes |
Same as for Record #4 |
15 |
Email between Amgen and DPB staff |
1 |
Access Denied |
Yes |
Same as for Record #4 |
16 |
Letter from DPB to Amgen |
1 |
Access Denied |
Yes |
17(1)(a)(c)
|
17 |
Internal email between DPB staff |
1 |
Access Denied |
Yes |
18(1)(c)(d)
|
18 |
Letter from DPB to Another Provincial Drug Program |
1 |
Disclose |
No |
28(1)(2) |
19 |
Internal email between DPB staff |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d) 2(1)(d) and 21(1)[21(2)(f)(h)] |
20 |
Letter from DPB to Health Canada |
1 |
Access Denied |
Yes |
18(1)(c)(d)
|
21 |
Email between Amgen and DPB staff |
2 |
Access Denied |
Yes |
Same as for Record #4 |
22 |
Letter from Amgen to DPB |
5 |
Access Denied |
Yes
|
17(1)(a)(c)
|
23 |
DQTC minutes of teleconference call |
2 |
Partial Disclosure e |
Yes |
17(1)(a)(b)(c) and 18(1)(c)(d)(g) 13(1) 2(1)(h)and 21(1)[21(2)(f)(h)] |
24 |
Letter from DPB to Amgen |
2 |
Access Denied |
Yes |
Same as for Record #4 |
25
|
Excerpt from DQTC Meeting Minutes |
5 |
Partial Disclosure e |
Yes |
17(1)(a)(b)(c) and 18(1)(c)(d)(g) 13(1) 2(1)(h)and 21(1)[21(2)(f)(h)] |
26 |
Letter from DPB to Amgen |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
27 |
Letter from Amgen to DPB |
19 |
Access Denied |
Yes |
Same as for Record #4
|
28 |
Letter from Amgen to DPB |
2 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
29 |
Internal Emails between DPB staff + attachment |
5 |
Access Denied |
Yes |
Same as for Record #28 |
30 |
Letter from Amgen to DPB |
1 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(c)(d)(g) |
31 |
Letter from Amgen to Ministry |
2 |
Access Denied |
Yes |
Same as for Record #4 |
32 + 32a |
Internal memo to Minister of Health and Long-Term Care + Attachment |
45 |
Access Denied |
Yes |
18(1)(a)(c)(d)(g) 19 13(1) |
33 |
Letter to Amgen from the DPB |
2 |
Access Denied |
Yes |
17(1)(a)(c)
|
34 |
Letter from MOHLTC to Amgen |
5 |
Access Denied |
Yes |
17(1)(a)(b)(c) 18(1)(a)(c)(d)(g) 28(1)(2) |
35 |
December 20, 2002 – Briefing Note |
6 |
Partial Disclosure e |
Yes |
13(1) 17(1)(a)(b)(c) 18(1)(c)(d)(g) |
36 |
Letter to external stakeholders re SDP |
1 |
Disclose |
No |
|
37 |
Letter to pharmaceutical manufacturers re SDP |
2 |
Disclose |
No |
|
|
|
165 |
|
|
|